Coenzyme Q10 for heart failure

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Madmani, Mohammed E ^a   Yusuf Solaiman, Ahmad ^b   Tamr Agha, Khalil ^c   Madmani, Yasser ^d   Shahrour, Yasser ^e   Essali, Adib ^f   Kadro, Waleed ^g  

^a METROHEALTH MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^d BMJ Publishing   (United Kingdom)

^e Psychiatry Centre ^*  (Syrian Arab Republic)

^f Psychiatry Centre   (Syrian Arab Republic)

^g The Golden Cardiovascular Centre   (Syrian Arab Republic)

Author keywords

[No Author keywords available]

Indexed keywords

UBIDECARENONE; UBIQUINONE; VITAMIN;

ALL CAUSE MORTALITY; ASTHMA; CARDIOVASCULAR MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LUNG EDEMA; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; ATAXIA; COMPLICATION; DEFICIENCY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEART STROKE VOLUME; META ANALYSIS; MUSCLE WEAKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ATAXIA; HEART FAILURE; HUMANS; MITOCHONDRIAL DISEASES; MUSCLE WEAKNESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; UBIQUINONE; VITAMINS;

EID: 84942794917     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008684.pub2     Document Type: Review

References (91)

1. Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 2008;32(1-4):145-9.
2. Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, et al.Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology 2004;27(10):A26.
3. Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, et al.Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology 2004;27(5):295-9.
4. Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, et al.Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation 2003;12(3):135-41.
5. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW, et al.The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine 2000;132(8):636-40.
6. Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G, Kocharian Armen, et al.Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young 2009;19(5):501-6.
7. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator 1993;71(8 Suppl):S134-6.
8. Munkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9(2-4):285-9.
9. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Japanese Circulation Journal 1992;56(1):95-9.
10. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). The CoQ10 Drug Surveillance Investigators. Clinical Investigator 1993;71(8 Suppl):S145-9.
11. Belardinelli R, Mucaj A, Lacalaprice F, Solenghi M, Principi F, Tiano L, et al.Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005;25(1-4):137-45.
12. Belardinelli R, Tiano L, Littarru GP. Oxidative stress, endothelial function and coenzyme Q10. Biofactors 2008;32(1-4):129-33.
13. Cascone A, Cascone G, Alaimo A. Treatment of patients with congestive heart failure with coenzyme Q10 in an open trial [Italian]. Bollettino Chimico Farmaceutico 1985;124(5):43S-52S.
14. Chew GT, Watts GF, Davis TME, Stuckey BGA, Beilin LJ, Thompson PL, et al.Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008;31(8):1502-9.
15. Davini A, Cellerini F, Topi PL. Coenzyme Q10: contractile dysfunction of the myocardial cell and metabolic therapy [Italian]. Minerva Cardioangiologica 1992;40(11):449-53.
16. Hall JH, Judy WV, Folkers K. Long-term survival in coenzyme-Q10 treated congestive-heart-failure patients. Circulation 1990;82(4):675.
17. Hanping Z, Guolong Y, Jing L, Jin H. The changes of PRA, ATII, ALD, ET and ANP in patients with left ventricular and intervention with enalapril. Bulletin of Hunan Medical University 1997;22(4):323-6.
18. Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. Journal of Cardiac Failure 1995;1:101-7.
19. Ishiyama T, Morita Y, Toyama S, Yamagami T, Tsukamoto N. A clinical study of the effect of coenzyme Q on congestive heart failure. Japanese Heart Journal 1976;17(1):32-42.
20. Iwabuchi T. Clinical efficacy of coenzyme Q10 for cardiac failure: a double-blind controlled comparison. Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine) 1972;49(9):2604-8.
21. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger RS, Robinson SW, et al.Long-term efficacy of coenzyme Q 10 therapy for congestive heart failure. Circulation 1999;100(18):3411.
22. Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, et al.Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiologica 2007;62(4):349-54.
23. Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme-Q(10) as adjuvant therapy in heart-failure. Clinical Investigator 1993;71(8):S129-33.
24. Langsjoen PH, Vadhanavikit S, Folkers K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Under Experimental & Clinical Research 1985;11(8):577-9.
25. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proceedings of the National Academy of Sciences of the United States of America 1985;82(12):4240-4.
26. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klinische Wochenschrift 1988;66(13):583-90.
27. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. American Journal of Cardiology 1990;65(7):521-3.
28. Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Molecular Aspects of Medicine 1994;15 Suppl:s165-75.
29. Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-28.
30. Manzoli U, Rossi E, Littarru GP, Frustaci A, Lippa S, Oradei A, et al.Coenzyme Q10 in dilated cardiomyopathy. International Journal of Tissue Reactions 1990;12(3):173-8.
31. Mazzola C, Guffanti EE, Vaccarella A. Noninvasive assessment of coenzyme Q 10 in patients with chronic stable effort angina and moderate heart failure. Current Therapeutic Research, Clinical and Experimental 1987;41(6):923-32.
32. Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M, et al.Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Molecular Aspects of Medicine 1994;15 Suppl:s155-63.
33. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Under Experimental & Clinical Research 1985;11(8):581-93.
34. Nishimura T, Hori M. Therapeutic effects of coenzyme Q10 on dilated cardiomyopathy: assessment by 123I-BMIPP myocardial single photon emission computed tomography (SPECT): a multicenter trial in Osaka University Medical School Group [Japanese]. Kaku Igaku (Japanese Journal of Nuclear Medicine) 1996;33(1):27-32.
35. Permanetter B, Rossy W, Klein G, Weingartner F, Seidl KF, Blomer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. European Heart Journal 1992;13(11):1528-33.
36. Poggesi L, Galanti G, Comeglio M, Toncelli L, Vinci M. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. A medium-term randomized double-blind study versus placebo. Current Therapeutic Research, Clinical and Experimental 1991;49(5):878-86.
37. Sacher HL, Sacher ML, Landau SW, Kersten R, Dooley F, Sacher A, et al.The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. American Journal of Therapeutics 1997;4(2-3):66-72.
38. Schneeberger W, Zilliken F, Moritz J. Clinical studies with coenzyme Q10 in patients with congestive heart failure. Drugs Under Experimental and Clinical Research 1984;10(7):503-12.
39. Sinatra ST. Coenzyme Q10 and congestive heart failure. Annals of Internal Medicine 2000;133(9):745-6.
40. Sinatra ST, Berman M, Ben-Gal T. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study [2] (multiple letters). Clinical Cardiology 2004;27(10):A26+A30.
41. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN, et al.Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. Journal of the American College of Cardiology 1999;33(6):1549-52.
42. Witte KK, Nikitin NP, Parker AC, Von Haehling S, Volk HD, Anker SD, et al.The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. European Heart Journal 2005;26(21):2238-44.
43. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, et al.Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Canadian Journal of Cardiology 2006;22(1):23-45.
44. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. British Heart Journal 1991;65(5):245-8.
45. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, et al.Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Safety 2006;29(8):703-12.
46. Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007;7S:S78-88.
47. Boon NA, Colledge NR, Walker BR, Hunter JAA. Davidson's Principles and Practice of Medicine. 20th Edition. Churchill Livingstone, 2006.
48. Carbajal EV, Deedwania PC. Congestive heart failure. In: Crawford MH editor(s). Current Diagnosis and Treatment in Cardiology. 2nd Edition. New York: Lange Medical Books/McGraw-Hill, 2003:218-9.
49. BMJ Clinical Evidence. EBM Tools: Glossary. http://clinicalevidence.bmj.com/ceweb/resources/glossary.jsp#Random_effects (accessed 16 January 2010).
50. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. American Heart Journal 1996;131(1):146-52.
51. Drexler H, Hasenfuss G. Physiology of the normal and failing heart. In: Crawford MH, DiMarco JP, Paulus WJ editor(s). Cardiology. 2nd Edition. Edinburgh: Mosby, 2004:829.
52. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
53. Elesber AA, Redfield MM. Approach to patients with heart failure and normal ejection fraction. Mayo Clinic Proceedings 2001;76(10):1047-52.
54. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al.Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):8931-4.
55. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, et al.Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Annals of Internal Medicine 2002;137(8):631-9.
56. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. Journal of Clinical Pharmacology 1990;30(7):596-608.
57. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. American Journal of Health-System Pharmacy 2000;57(13):1221-7.
58. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 2006;12(1):10-38.
59. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. Journal of the American College of Cardiology 1993;22:6A-13A.
62. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
63. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Research Communications in Chemical Pathology and Pharmacology 1977;17(1):157-64.
64. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
65. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al.Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215.
66. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. American Heart Journal 1997;133:703-12.
67. McMurray J, McLay J, Chopra M, Bridges A, Belch JJ. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology 1990;65(18):1261-2.
68. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. European Heart Journal 1993;14(11):1493-8.
69. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. European Heart Journal 1998;19 Suppl P:P9.
70. Migliore L, Molinu S, Naccarati A, Mancuso M, Rocchi A, Siciliano G. Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis 2004;19(1):43-9.
71. Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet 1998;352:609-13.
72. Mortensen SA, Vadhanavikit S, Folkers K. Deficiency of coenzyme Q10 in myocardial failure. Drugs Under Experimental and Clinical Research 1984;X(7):497-502.
73. Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. International Journal of Tissue Reactions 1990;12(3):155-62.
74. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clinical Investigator 1993;71(8 Suppl):S116-23.
75. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine 1997;18(Suppl):S137-44.
76. Niklowitz P, Sonnenschein A, Janetzky B, Andler W, Menke T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. International Journal of Biological Sciences 2007;3(4):257-62.
77. Nishiyama Y, Ikeda H, Haramaki N, Yoshida N, Imaizumi T. Oxidative stress is related to exercise intolerance in patients with heart failure. American Heart Journal 1998;135(1):115-20.
78. Criteria Committee, New York Heart Association. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th Edition. Boston: Little, Brown and Co, 1964.
79. Rauchova H, Drahota Z, Lenaz G. Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiological Research 1995;44(4):209-16.
80. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289(2):194-202.
81. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
82. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al.Report of the 1995 Word Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
83. Rodriguez-Artalejo F, Banegas Banegas JR, Guallar-Castillon P. Epidemiology of heart failure [Epidemiologia de la insuficiencia cardiaca]. Revista Espanola de Cardiologia 2004;57(2):163-70.
84. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
85. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(2):203-8.
86. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al.Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European Heart Journal 2005;26(11):1115-40.
87. Tappel AL. Vitamin E and free radical peroxidation of lipids. Annals of The New York Academy of Sciences 1972;203:12-21.
88. Teerlink JR, Goldhaber SZ, Preffer MA. An overview of contemporary etiologies of congestive heart failure. American Heart Journal 1991;121:1852-3.
89. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al.Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Journal of the American College of Cardiology 2002;39(6):957-62.
90. Vasan RS, Benjamin EJ, Levy D. Prevalence clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. Journal of the American College of Cardiology 1995;26(7):1565-74.
91. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. New England Journal of Medicine 2005;353(26):2788-96.